Duloxetine Capsule, Delayed Release
Product Images NDC 68071-3979

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-3979). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3979 6)

This is information about a medication called Duloxetine in the form of capsules, each containing 20mg of Duloxetine Hydrochloride. The capsules also have Enteric-Coated Pellets. The prescription medicine is to be stored at a controlled temperature of 68-77°F and kept out of reach of children. More details can be found on the manufacturer's label.*

FDA Label Image

Figure1 (Duloxetine Fig1)

This text provides data on the number of patients with relapse over time after randomization and treatment with either a placebo or duloxetine. The graph shows the time in days from randomization to relapse, with markers at 100, 150, and 200 days. It appears to be a study or clinical trial comparing the efficacy of duloxetine versus a placebo in preventing relapse in patients.*

FDA Label Image

Figure10 (Duloxetine Fig10)

This is a description of a medication regime involving Placebo and Duloxetine 60/120 mg taken once daily. It also includes a chart showing Percent Improvement in Pain from Baseline (BOCF). The text provides details about dosages and specifies the timeframes for potential pain improvement.*

FDA Label Image

Figure2 (Duloxetine Fig2)

This is a graph showing the proportion of patients experiencing a relapse over time for both placebo and duloxetine treatments. The x-axis represents the time from randomization to relapse in days, while the y-axis shows the proportion of patients with relapse. The graph suggests that duloxetine treatment may be associated with a lower proportion of patients experiencing a relapse compared to placebo over a 300-day period.*

FDA Label Image

Figure3 (Duloxetine Fig3)

Percentage of Patients Improved: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, Placebo. The data indicates the percent improvement in pain from baseline for these different medications.*

FDA Label Image

Figure4 (Duloxetine Fig4)

FDA Label Image

Figure5 (Duloxetine Fig5)

This is a comparison chart showing the percentage of patients improved in pain from baseline when taking Duloxetine 60mg twice daily, Duloxetine 60mg once daily, or a placebo. The chart indicates the level of improvement for each treatment option.*

FDA Label Image

Figure6 (Duloxetine Fig6)

FDA Label Image

Figure7 (Duloxetine Fig7)

This text shows a table displaying the percentage of patients improved with Duloxetine 60 mg once daily compared to placebo in terms of pain improvement. The percentage of improvement is shown from 0 to 100, with a range of values between 10 to 90. The table includes data points such as 210, 220, 230, 240, 250 indicating improvement levels.*

FDA Label Image

Figure8 (Duloxetine Fig8)

This is a description of a medical treatment regimen involving the administration of placebo or Duloxetine in doses of 60/120 mg once daily. The text also mentions a measurement of pain improvement from baseline.*

FDA Label Image

Figure9 (Duloxetine Fig9)

This text provides information about a comparison between a placebo and Duloxetine 60 mg taken once daily. It seems to be related to pain relief assessment based on the percent improvement in pain from baseline.*

FDA Label Image

Structure (Duloxetine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.